Lilly(US:LLY) Benzinga·2025-11-19 15:02Core Insights - Deep-pocketed investors are showing a bullish sentiment towards Eli Lilly, indicating potential significant developments ahead [1] - The options activity for Eli Lilly is unusually high, with a split sentiment among investors [2] Options Activity - A total of 21 extraordinary options activities were recorded for Eli Lilly, with 33% of investors bullish and 33% bearish [2] - Notable options include 2 puts totaling $83,620 and 19 calls amounting to $1,322,319 [2] Price Targets - Investors have been targeting a price range for Eli Lilly between $620.0 and $1220.0 over the last three months based on volume and open interest [3] Volume and Open Interest Analysis - The analysis of volume and open interest provides insights into the liquidity and interest in Eli Lilly's options [4] Largest Options Trades - Significant trades include bullish call options with various strike prices and expiration dates, indicating strong investor interest [8] Company Overview - Eli Lilly focuses on neuroscience, cardiometabolic, cancer, and immunology, with key products including Verzenio, Mounjaro, and Trulicity [10] Current Analyst Ratings - Analysts have issued ratings for Eli Lilly with a consensus target price of $1186.8, with several maintaining buy ratings and higher target prices [11][12] Stock Performance - Eli Lilly's stock price is currently at $1040.51, reflecting a 1.01% increase, with a trading volume of 302,009 [14]